Allo-SCT was found to be associated with significantly improved EFS and OS in patients with NPM1-mutated/FLT3-ITD mutated (Group 2) and FLT3-ITD mutated (Group 3) AML, in agreement with previously reported data demonstrating improved long-term outcomes with allo-SCT for FLT3-ITD AML [30,31,32]. This evidence concerns the gene FLT3 and acute myeloid leukemia.